Medicaid

Optum
Pharmalot

A big PBM wants drug makers to agree to rebate demands that would preserve its bottom line

By Ed Silverman and Ike Swetlitz

Cloud of obscurity
First Opinion

‘Cloud of secrecy’ in Medicare Advantage plans can create an environment for fraud

By Jeanne A. Markey and Raymond M. Sarola

Hep C San Fran
Pharmalot

Washington state becomes the latest to embrace a Netflix model for buying hep C drugs

By Ed Silverman

Pharmalot

Pharmalittle: Senate committee ‘reinvites’ big drug makers to testify; can pharma use AI to solidify patents?

By Ed Silverman

Priceberg
First Opinion

We’re missing the true point of hospital price transparency

By Jay Deady

Marylou Sudders
Pharmalot

Here’s how Massachusetts officials hope to lower their Medicaid drug spending

By Ed Silverman

Pharmalot

Pharmalittle: Massachusetts seeks to negotiate directly with pharma; Civica looks to make 20 generics

By Ed Silverman

Pharmacy shelves
Pharmalot

Pharmacy benefit managers marked up generic drugs for NY Medicaid, but where’d the money go?

By Ed Silverman

WALGREENS
Pharmalot

Walgreens pays $269 million to settle charges of overbilling government health programs

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan

By Ed Silverman

Pharmalot

Pharmalittle: Drug prices may rise up to 9 percent next month; Novartis seeks to boost CAR-T manufacturing

By Ed Silverman

Senators Opioid Report
Pharmalot

Wyden probes ties between opioid makers, advocacy groups, and a government panel

By Ed Silverman

Pharmalot

Feds want to dismiss lawsuits alleging nurse educator programs are kickback schemes

By Ed Silverman

Pharmalot

Pharmalittle: House moves bill to thwart Medicaid misclassifications; McDonald’s to cut antibiotic use in beef

By Ed Silverman

CVS Miami
Pharmalot

Pennsylvania auditor recommends new laws to crack down on PBM contracts for Medicaid

By Ed Silverman

Pharmalot

Pharmalittle: Takeda shareholders approve Shire deal; HPV vaccine program in Quebec divides experts

By Ed Silverman

Pharmalot

Justice Department tells Supreme Court it wants to scuttle a whistleblower case against Gilead

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo buys Tesaro for $5.1 billion; showdown as Takeda deal for Shire nears

By Ed Silverman

Pharmalot

Pharmalittle: Novartis pricing is being tested; Trump team looks to relax kickback rules

By Ed Silverman

Pharmalot

Pharmalittle: FDA still has concerns about compounders; Takeda bid for Shire wins advisory backing

By Ed Silverman

Kaleo Naloxone Donation 02
Pharmalot

A drug maker boosted the price of its opioid-overdose antidote by 600 percent, and taxpayers suffered

By Ed Silverman

Pharmalot

HHS watchdog chastises Mallinckrodt over a giveaway program for its pricey Acthar Gel drug

By Ed Silverman

Pharmalot

Pharmalittle: Novartis denies plan to spin off Sandoz; next House E&C chair eyes Medicare price negotiations

By Ed Silverman

Politics

In Michigan, Medicaid can now pay for drugs based on how well they work

By Ike Swetlitz

Pharmalot

Pharmalittle: Lawmakers pressed on drug-cost pledges; Walmart and Home Depot embrace co-pay accumulators

By Ed Silverman

Hep C San Fran
Pharmalot

Fewer state Medicaid programs restrict access to hep C meds, but some hurdles still exist

By Ed Silverman

Midterms results illo
Politics

Election rundown: How voters cast their ballots on health care issues and candidates

By Andrew Joseph

Montana Medicaid
First Opinion

Voters should seize the opportunity to expand Medicaid

By Rod Hochman

Pharmalot

AbbVie and Abbott pay $25 million to resolve claims of illegally marketing a cholesterol pill

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy